Open Access
Med Sci (Paris)
Volume 35, Number 5, Mai 2019
Page(s) 431 - 439
Section M/S Revues
Published online 22 May 2019
  1. World health organization Global hepatitis report, 2017. 2017 ; Geneva: WHO, [Google Scholar]
  2. European Association for the Study of the Liver EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012 ; 57 : 167–185. [CrossRef] [PubMed] [Google Scholar]
  3. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012: Globocan 2012. Int J Cancer. 2015 ; 136 : E359–E386. [CrossRef] [PubMed] [Google Scholar]
  4. Graber-Stiehl I.. The silent epidemic killing more people than HIV, malaria or TB. Nature. 2018 ; 564 : 24. [CrossRef] [PubMed] [Google Scholar]
  5. Kiire CF. The epidemiology and prophylaxis of hepatitis B in sub-Saharan Africa: a view from tropical and subtropical Africa. Gut. 1996 ; 38 : S5–12. [CrossRef] [PubMed] [Google Scholar]
  6. Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015 ; 386 : 1546–1555. [CrossRef] [PubMed] [Google Scholar]
  7. Bah E, Carrieri MP, Hainaut P, et al. 20-years of population-based cancer registration in hepatitis B and liver cancer prevention in the Gambia. West Africa. PLoS One. 2013 ; 8 : e75775. [CrossRef] [PubMed] [Google Scholar]
  8. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015 ; 65 : 87–108. [CrossRef] [PubMed] [Google Scholar]
  9. International Agency for Research on Cancer Some traditional herbal medicines, some mycotoxins, naphthalene and styrene: this publication represents the views and expert opinions of an IARC working group on the evaluation of carcinogenic risks to hHumans, which met in Lyon, 12–19 February 2002. 2002 ; Lyon: IARC: 590. [Google Scholar]
  10. Kirk GD, Lesi OA, Mendy M, et al. 249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. Oncogene. 2005 ; 24 : 5858–5867. [Google Scholar]
  11. Kuniholm MH, Lesi OA, Mendy M, et al. Aflatoxin exposure and viral hepatitis in the etiology of liver cirrhosis in the Gambia. West Africa. Environ Health Perspect. 2008 ; 116 : 1553–1557. [CrossRef] [PubMed] [Google Scholar]
  12. Liaw YF, Sung JJY, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004 ; 351 : 1521–1531. [CrossRef] [PubMed] [Google Scholar]
  13. Robotin MC, Kansil MQ, George J, et al. Using a population-based approach to prevent hepatocellular cancer in New South Wales, Australia: effects on health services utilisation. BMC Health Serv Res. 2010 ; 10 : 215. [CrossRef] [PubMed] [Google Scholar]
  14. Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma: an updated analysis of randomized controlled trials. Aliment Pharmacol Ther. 2006 ; 23 : 1535–1547. [Google Scholar]
  15. EASL, EORTC. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56 : 908–43. [CrossRef] [PubMed] [Google Scholar]
  16. Yang JD, Mohamed EA, Aziz AOA, et al. Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. Lancet Gastroenterol Hepatol. 2017 ; 2 : 103–111. [CrossRef] [PubMed] [Google Scholar]
  17. Shimakawa Y, Takao Y, Anderson ST, et al. The prevalence and burden of symptoms in patients with chronic liver diseases in The Gambia. West Africa. Palliat Med. 2015 ; 29 : 184–185. [CrossRef] [PubMed] [Google Scholar]
  18. Shimakawa Y, Lemoine M. Early age at diagnosis of hepatocellular carcinoma in sub-Saharan Africa. Lancet Gastroenterol Hepatol. 2017 ; 2 : 393. [CrossRef] [PubMed] [Google Scholar]
  19. Njai HF, Shimakawa Y, Sanneh B, et al. Validation of rapid point-of-care (POC) tests for detection of hepatitis B surface antigen in field and laboratory settings in the Gambia. Western Africa. J Clin Microbiol. 2015 ; 53 : 1156–1163. [PubMed] [Google Scholar]
  20. Ladep NG, Dona AC, Lewis MR, et al. Discovery and validation of urinary metabotypes for the diagnosis of hepatocellular carcinoma in West Africans. Hepatology. 2014 ; 60 : 1291–1301. [CrossRef] [PubMed] [Google Scholar]
  21. Keane E, Funk AL, Shimakawa Y. Systematic review with meta-analysis: the risk of mother-to-child transmission of hepatitis B virus infection in sub-Saharan Africa. Aliment Pharmacol Ther. 2016 ; 44 : 1005–1017. [Google Scholar]
  22. Lemoine M, Shimakawa Y, Njie R, et al. Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the prevention of liver fibrosis and cancer in Africa (PROLIFICA) study. Lancet Glob Health. 2016 ; 4 : e559–e567. [CrossRef] [PubMed] [Google Scholar]
  23. Shimakawa Y, Pourette D, Bainilago L, et al. Improving communication about viral hepatitis in Africa. Lancet Infect Dis. 2017 ; 17 : 688–689. [CrossRef] [PubMed] [Google Scholar]
  24. Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009 ; 50 : 1–662. [PubMed] [Google Scholar]
  25. Marcellin P, Zoulim F, Hézode C, et al. Effectiveness and safety of Tenofovir Disoproxil Fumarate in chronic hepatitis B: A 3-year, prospective, real-world study in France. Dig Dis Sci. 2016 ; 61 : 3072–3083. [CrossRef] [PubMed] [Google Scholar]
  26. Nayagam S, Thursz M, Sicuri E, et al. Requirements for global elimination of hepatitis B: a modelling study. Lancet Infect Dis. 2016 ; 16 : 1399–1408. [CrossRef] [PubMed] [Google Scholar]
  27. Nayagam S, Conteh L, Sicuri E, et al. Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in the Gambia: an economic modelling analysis. Lancet Glo Health. 2016 ; 4 : e568–e578. [CrossRef] [Google Scholar]
  28. Ghosh S, Sow A, Guillot C, et al. Implementation of an in-house quantitative real-time polymerase chain reaction method for hepatitis B virus quantification in West African countries. J Viral Hepat. 2016 ; 23 : 897–904. [CrossRef] [PubMed] [Google Scholar]
  29. Ni Y, Sonnabend J, Seitz S, et al. The pre-S2 domain of the hepatitis B virus is dispensable for infectivity but serves a spacer function for L-protein-connected virus assembly. J Virol. 2010 ; 84 : 3879–3888. [PubMed] [Google Scholar]
  30. Hsieh YH, Chang YY, Su IJ, et al. Hepatitis B virus pre-S 2 mutant large surface protein inhibits DNA double-strand break repair and leads to genome instability in hepatocarcinogenesis: HBV pre-S2 mutant LHBS, Nijmegen breakage and importin α1. J Pathol. 2015 ; 236 : 337–347. [PubMed] [Google Scholar]
  31. Shariff MIF, Ladep NG, Cox IJ, et al. Characterization of urinary biomarkers of hepatocellular carcinoma using magnetic resonance spectroscopy in a Nigerian population. J. Proteome Res.. 2010 ; 9 : 1096–1103. [Google Scholar]
  32. Shimakawa Y, Njie R, Ndow G, et al. Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa. Journal of Hepatology. 2018 ; 69 : 776–784. [CrossRef] [PubMed] [Google Scholar]
  33. Lemoine M, Shimakawa Y, Njie R, et al. Food intake increases liver stiffness measurements and hampers reliable values in patients with chronic hepatitis B and healthy controls: the PROLIFICA experience in the Gambia. Aliment Pharmacol Ther. 2014 ; 39 : 188–196. [Google Scholar]
  34. Lemoine M, Shimakawa Y, Goldin R, et al. P1019 validation and comparison of non-invasive markers of liver fibrosis in West-African patients with chronic hepatitis B living in the Gambia. J Hepatol. 2014 ; 60 : S414–S415. [Google Scholar]
  35. Lemoine M, Shimakawa Y, Nayagam S, et al. The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa. Gut. 2016 ; 65 : 1369–1376. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.